TXG — 10x Genomics, Inc.

1. Key Financial Results and Metrics

• Revenue: $151 million for Q1 2026, a 9% year-over-year increase when excluding nonrecurring settlement revenue from Q1 2025.
• Consumables Revenue: Up 13%, with single cell consumables growing 6% and spatial consumables increasing 31%.
• Instrument Revenue: Declined 24%, with a 12% drop in Chromium instruments and a 32% decline in spatial instruments.
• Gross Margin: Improved to 70% from 68% year-over-year, driven by lower warranty costs and inventory write-downs.
• Operating Expenses: Decreased 15%, primarily due to lower legal and personnel costs.
• Cash Position: Ended the quarter with $540 million in cash, up $113 million year-over-year.

2. Strategic Updates and Business Highlights

• Product Launch: Introduced Atara, a significant new instrument platform enabling spatial whole transcriptome analysis with single-cell sensitivity at scale. Early customer feedback has been overwhelmingly positive.
• Market Expansion: Atara is expected to expand the addressable market across discovery research, translational research, and AI-driven applications.
• Partnerships: Engaged in multiple collaborations, including with the Chan Zuckerberg Initiative and Biooptimus, to support large-scale data generation for AI models.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Maintained at $600 million to $625 million, reflecting 0% to 4% growth over 2025. Anticipated double-digit growth in both single cell and spatial consumables.
• Q2 and Q3 Expectations: Revenue is expected to decline sequentially due to customers delaying spatial purchases in anticipation of Atara.
• Q4 Outlook: Initial shipments of Atara are expected to contribute meaningfully to revenue, although production capacity will be limited in 2026.

4. Bad News, Challenges, or Points of Concern

• Instrument Revenue Decline: A significant drop in spatial instrument revenue, attributed to customer anticipation of Atara, which may affect short-term sales.
• Market Conditions: Persistent macroeconomic challenges and constrained capital expenditures may impact customer purchasing behavior.
• Operational Risks: Initial production capacity for Atara is limited, raising concerns about meeting demand in the near term.

5. Notable Q&A Insights

• Customer Interest in Atara: High interest across various market segments, with many customers eager to integrate Atara into their research programs.
• Impact on Existing Products: Anticipated cannibalization of existing spatial products like Xenium and Visium, but management believes the overall market will expand with Atara's capabilities.
• Cost Management: While inflationary pressures on materials are being monitored, gross margins are expected to remain stable in the mid-60s for the year.
• AI Integration: AI is seen as a significant growth driver, with increasing demand for high-quality biological data to support AI models.

Overall, 10x Genomics reported a strong start to 2026 with solid revenue growth and the successful launch of Atara, although challenges remain in instrument sales and production capacity.